Key facts
- This page summarizes James R. Tobin's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 May 2025, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.